Valuation: Forte Biosciences, Inc.

Market Cap 511M 448M 412M 383M 727M 48.76B 737M 4.94B 1.92B 23.94B 1.92B 1.88B 82.99B P/E 2026 *
-5.09x
P/E 2027 * -4.92x
Enterprise Value 511M 448M 412M 383M 727M 48.76B 737M 4.94B 1.92B 23.94B 1.92B 1.88B 82.99B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day-2.44%
1 week-4.27%
Current month-3.95%
1 month+30.25%
3 months-22.81%
6 months-13.00%
Current year-25.16%
1 week 19.95
Extreme 19.95
22.38
1 month 15.51
Extreme 15.51
22.38
Current year 15.51
Extreme 15.51
35.8
1 year 9.1
Extreme 9.1
35.8
3 years 4.11
Extreme 4.11
35.8
5 years 4.11
Extreme 4.11
921.25
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 01/01/2018
Director of Finance/CFO 59 01/03/2020
Chief Operating Officer - 01/10/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 01/06/2020
Director/Board Member 79 16/03/2022
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Chief Executive Officer

500,000 2.4415%
06-16Free

Chief Financial Officer

22,000 0.1074%
05-29Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-2.44%-4.27%+61.34%-18.36% 511M
-2.14%+3.65%+74.05%+131.89% 59.1B
-0.93%+4.05%+73.64%+90.53% 55.19B
-3.71%-0.35%-14.65%-11.19% 24.67B
-0.05%+6.49%+15.05%+451.36% 24.19B
+0.64%+14.41%+44.27%-3.20% 19.69B
-2.19%+7.37%+40.74%-30.67% 17.56B
+3.58%+25.11%+196.41%+363.46% 16.22B
+4.91%+25.24%+44.61% - 14.84B
-0.57%+2.30%+25.75%+187.27% 14.04B
Average -0.32%+8.73%+56.12%+129.01% 24.6B
Weighted average by Cap. -0.73%+6.44%+58.01%+135.60%

Financials

2026 *2027 *
Net sales - -
Net income -95.54M -83.67M -77.07M -71.54M -136M -9.11B -138M -923M -359M -4.47B -359M -351M -15.51B -130M -114M -105M -97.66M -185M -12.44B -188M -1.26B -490M -6.11B -490M -479M -21.17B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
22
Date Price Change Volume
07/07/26 US$20.41 -2.44% 242,497
02/07/26 US$20.92 -1.88% 401,572
01/07/26 US$21.32 +0.33% 339,474
30/06/26 US$21.25 -0.33% 421,439
29/06/26 US$21.32 +1.38% 474,506
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.92USD
Average target price
63.75USD
Spread / Average Target
+204.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock